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Abstract
Background: We conducted a retrospective analysis on 884 patients who were diagnosed with esophageal
squamous cell carcinoma (ESCC) and treated with either the neutron brachytherapy in combination with
external beam radiotherapy (NBT + EBRT) or 3-dimensional conformal radiation therapy (3D-CRT) to determine
the differences in efficacy and morbidity between the two treatment groups.
Methods: The 884 ESCC patients treated with either NBT + EBRT or 3D-CRT between 2002 and 2012 were
retrospectively reviewed and analyzed. Multivariable Cox regression was used to compare oncologic outcomes
of the two groups of patients in the context of other clinically relevant variables. The acute and chronic
toxicities associated with the two groups were compared using Fisher exact and log-rank tests, respectively.
Results: Among the 884 patients, 545 received NBT + EBRT and 339 received 3D-CRT (i.e. EBRT-only). The age
range is 39–95 years (median 66). The follow-up time range is 3–145 months (median 32). The analysis shows
that the NBT + EBRT group has higher overall survival rate and local control rate than that of the 3D-CRT group.
The acute toxicity effects were acceptable for both groups of patients with the NBT + EBRT group showing
higher rates of leukopenia and thrombocytopenia and the 3D-CRT group showing higher rates on fistula and
massive bleeding.
Conclusions: The patients treated with NBT + EBRT showed better oncologic outcomes than those treated
with 3D-CRT. The toxicity effects were acceptable for both groups with the NBT + EBRT group showing higher
rates on the acute effects and the 3D-CRT group showing higher rates on the late effects.
Keywords: Esophageal squamous cell carcinoma (ESCC), Neutron brachytherapy (NBT), High-LET, Relative
biological effectiveness (RBE)
Background
Worldwide, an estimated 482,000 new esophageal cancer
cases were diagnosed and approximately 407,000 deaths
occurred in 2008 [1]. The management of localized
esophageal cancers has shifted from surgery or radiation
single modality approaches to the trimodality. The current
trimodality approach combining chemotherapy, radiation
therapy, and surgery, has shown improved survival rates
[2]. However, there are patients that either cannot tolerate
or decide not to undergo surgery. For these individuals,
concurrent chemoradiotherapy (CCRT) is the standard
approach.
In recent years, two radiotherapy modalities have become
widely used in China to treat esophageal cancers: the
neutron brachytherapy in combination with conventional
external beam radiotherapy (NBT + EBRT) and the 3-
dimensional conformal radiotherapy (3D-CRT). Currently
there are no prospective, randomized trials comparing the
efficacy of the two modalities for the treatment of esopha-
geal cancer. The choice between the two modalities is not
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trivial, and their characteristics can have bearing on both
disease control and adverse effects [3]. Generally speaking,
3D-CRT tends to treat lymph nodes adjacent to the target
with relatively high doses, whereas EBRT tends to cover
farther regional nodes with lower doses [4, 5]. Because the
radiation dose of NBT is highly localized, the NBT + EBRT
has a benefit of sculpting away high-dose regions from
normal tissues, e.g. the heart and lungs. In addition to
clinical considerations, there are also substantial differ-
ences between NBT + EBRT and 3D-CRT (i.e. EBRT-only)
in terms of the allocations of time, labor, and health care
costs. Accordingly, we conducted a retrospective study on
patients of esophageal squamous cell carcinoma (ESCC)
who were treated with either NBT + EBRT or 3D-CRT to




From January 2002 to November 2012, two groups of
patients diagnosed with localized ESCC were treated
separately at two different hospitals and with two different
radiotherapy modalities. The first group of 545 patients
were treated at the Changzhi Cancer Hospital with NBT +
EBRT, and the second group of 339 patients were treated at
the Sichuan cancer hospital with 3D-CRT (i.e. EBRT-only).
All 884 patients had histologically confirmed ESCC meas-
uring 10 cm or less in length. The primary tumors of the
Table 1 The characteristics of patients of the two treatment groups (EBRT + NBT and 3D-CRT) and the univariate analysis of the
clinical outcome
Characteristics Total (%) EBRT + NBT (%) 3D-CRT (%) P value* 5y OS (%) P value 5y LC (%) P value
Gender <0.0001 0.174 0.312
Male 583 (66.0) 324 (59.4) 259 (76.4) 24.5 44.7
Female 301 (34.0) 221 (40.6) 80 (23.6) 30.8 51.9
Age (years) 0.003 0.291 0.591
≤65 426 (48.2) 284 (52.1) 142 (41.9) 29.9 48.3
>65 458 (51.8) 261 (47.9) 197 (58.1) 23.5 46.4
Tumor length 0.220 <0.0001 <0.0001
≤5 cm 409 (46.3) 261 (47.9) 148 (43.7) 31.0 52.4
>5 cm 475 (53.7) 284 (52.1) 191 (56.3) 22.9 42.4
Tumor location <0.0001 0.233 0.581
Upper 329 (37.2) 174 (31.9) 155 (45.7) 26.9 49.2
Middle 442 (50.0) 309 (56.7) 133 (39.2) 27.8 45.6
Lower 113 (12.8) 62 (11.4) 51 (15.0) 20.9 46.4
T stage 0.006 <0.0001 <0.0001
T1 32 (3.6) 20 (3.7) 12 (3.5) 64.1 73.1
T2 163 (18.4) 107 (19.6) 56 (16.5) 32.9 51.7
T3 305 (34.5) 164 (30.1) 141 (41.6) 31.2 53.9
T4 384 (43.4) 254 (46.6) 130 (38.3) 17.6 37.7
N stage <0.0001 <0.0001
N0 461 (52.1) 338 (62.0) 123 (36.3) 32.6 53.2
N1 423 (47.9) 207 (38.0) 216 (63.7) 20.2 40.0
AJCC stage <0.0001 <0.0001 <0.0001
I 28 (3.2) 20(3.7) 8 (2.4) 72.3 74.5
IIa 280 (31.7) 195 (35.8) 85 (25.1) 36.0 56.6
IIb 55 (6.2) 22 (4.0) 33 (9.7) 29.3 35.2
III 521 (58.9) 308 (56.5) 213 (62.8) 19.2 41.1
Radiation dose <0.0001 0.263 0.658
≤60Gy 321 (36.3) 91 (16.7) 230 (67.8) 22.9 44.7
>60Gy 563 (63.7) 454 (83.3) 109 (32.2) 29.0 48.6
Abbreviations: EBRT + NBT external beam radiotherapy plus neutron brachytherapy; 3D-CRT three dimensional conform radiotherapy
P value*: the P values corresponding to the log-rank test between the two treatment groups (EBRT + NBT and 3D-CRT)
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patients were limited to the esophagus, with or without the
presence of involved regional lymph nodes, i.e., T2-4, N0-1,
M0 according to the 2002 American Joint Committee on
Cancer (AJCC) clinical staging system. All of the patients
had good performance status (i.e. being able to care for
himself or herself) as well as adequate hepatic, renal, and
hematologic functions. All patients gave their informed
consents before treatment in accordance with the Declar-
ation of Helsinki. The informed consents were also ap-
proved by the respected Ethics Committees of Changzhi
Cancer Hospital and Sichuan Cancer Hospital. The detailed
demographic data and tumor characteristics of the patients
are given in Table 1.
Radiotherapy
Group 1: NBT + EBRT
For the patients treated with NBT + EBRT, NBT and
EBRT were interchangeably implemented over the treat-
ment time period. Specifically, patients who were able to
take normal food or soft diet underwent one fraction of
NBT and five fractions of EBRT per week. A nominal
treatment lasted for 5 weeks, and it included five frac-
tions of NBT and 25 fractions of EBRT. Some patients
who were only able to take liquid diet were first treated
with EBRT-only for 2 or 3 weeks and then followed with
NBT + EBRT for the next 2 or 3 weeks. Since these pa-
tients only received two or three fractions of NBT, the
dose for each NBT fraction was adjusted accordingly [4].
The EBRT was carried out by a 6 MV linear accelerator.
The treatment field size was determined according to
the CT and barium swallow test results. Two-field tech-
nique (one anterior field and one posterior field) or
three-field technique (one anterior field and two poster-
ior fields) was used to treat the upper segment of the
esophagus. Only the three-field technique (one anterior
field and two posterior fields) was used to treat the mid-
dle and lower segments of the esophagus. The upper
and lower boundaries of the treatment field were deter-
mined by adding 3–5 cm from the visible disease area
shown on the CT/barium swallow images. In general,
the width of the treatment field was 6–7 cm, and the
total length was approximately 15 cm. The EBRT follows
the normal fractionation with five fractions per week,
one fraction per day, 1.8–2.0 Gy per fraction, a total of
20–28 fractions, and the total treatment time of 4–6
weeks. The total dose via EBRT was 40–56 Gy delivered
over a period of 4–6 weeks with normal fractionation.
The NBT was implemented with a one-balloon applica-
tor (Fig. 1) in conjunction with the 252Cf-based LZH-
1000 remote after-loading system (Linden Science and
Technology Co, Shenzhen, China). The water balloon is
an essential part of the applicator because for tumors
that are eccentric with respect to the axis of esophagus
the water balloon can be inflated accordingly to keep the
source close to the tumor but away from the adjacent
normal epithelium. Figure 1 is an x-ray image taken while
the applicator and a dummy source were both inserted
into the esophagus of a patient. The water balloon can
clearly be seen as it is filled with an x-ray contrast agent.
The position of the source capsule was then determined
(based on the x-ray image) and input into the treatment
planning system. The radiation dose was prescribed to the
reference point, which was located 10 mm from the center
point of the source capsule in the transverse direction.
The physical characteristics of neutrons and gamma rays
emitted from 252Cf, the characteristics of the applicator
and the process of NBT, and the method converting
absorbed neutron dose (in Gy) to the equivalent gamma-
ray dose (in Gy-eq) were described in detail by Liu et. al.
[4]. Specifically, the neutron RBE value varies from 2.9
(for the new source) to 4.3 (for the 10-year-old source),
and it was calculated based on an algebraic formula in-
cluded in the treatment planning system. The treat-
ment time for each fraction varies from a few minutes
(for the new source) to about an hour (for the 10-year-
old source). The total dose received by each patient via
NBT varies between 8 and 25 Gy-eq, which were delivered
in two to five treatment fractions, with 4–5 Gy-eq per
fraction per week.
Fig. 1 The x-ray image showing the tumor regression conditions
before each of the 2–5 treatment fractions of NBT
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Group 2: 3D-CRT (i.e. EBRT-only)
For the patients treated with 3D-CRT, simulation CT
scanning was first performed with the CT Brilliance
Scanner (Philips Medical Systems, the Netherlands)
and with the use of intravenous contrast. All patients were
immobilized in a supine position (with thermoplastic
on the chest) when simulation and radiotherapy was
performed. The scanned area was from the angulus
mandibulae to the bottom of the L1 vertebral body.
These images were transferred to a 3-D treatment plan-
ning system. The clinical target volume (CTV) in this
study was re-created using a 3-cm margin in the prox-
imal and distal direction (following the course of the
esophagus) beyond the barium esophagram, endoscopic
examination and the gross tumor volume (GTV) defined
by a 0.5-cm margin in the lateral and anteroposterior di-
rections of the CT scan. Finally, the planning treatment
volume (PTV) was defined by including additional 1-cm
proximal and distal margins and 0.5-cm radial margin
based on the CTV. The prescribed radiation doses were
delivered by 6-MV X-rays from a linear accelerator (Elekta
Precise Linear Accelerator, Sweden). For each patient the
PTV was covered by at least 95 % isodose surface, and
95 % of the PTV received the 56–60 Gy of the prescribed
dose with 2 Gy/fraction/day and 5 days per week.
Toxicity assessment and follow-up
The patients were examined weekly during the course of
treatment. Weekly blood tests were obtained, and any
indication of treatment-related complications was re-
corded. All adverse events were graded according to the
National Cancer Institute’s Common Terminology Criteria
for Adverse Events, version 3.0 [6]. The patients usually
underwent follow-up examinations every 3–6 months
after the completion of treatment. Tumor response and
nodal disease were evaluated with repeated CT scans, bar-
ium swallow studies, and endoscopy.
Statistical analysis
Patients were grouped according to different radiotherapy
regimes. Pearson’s chi-square test was used to assess the
relationship between frequency data. The overall survival
(OS) time was calculated from the date of consultation
until death or the last follow-up. Local and regional failure
was defined as persistent and/or the recurrence of primary
tumor and regional lymph nodes. Time to first failure,
time to local failure, and time to any distant metastases
were calculated from the date of consultation. The OS rate
and the local control (LC) rate were estimated using the
Kaplan-Meier method. Nine factors were included for
the univariate analysis of OS and LC, like gender, age,
Karnofsky performance score (KPS), tumor location,
tumor length, T stage, N stage, AJCC stage, and radiation
dose. The log-rank test was used to assess the survival
differences between groups. Data were analyzed using
SPSS software (version 20.0, SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics and treatments
Table 1 shows the characteristics of the patients according
to the two different treatment modalities. As shown, there
were 583 men and 301 women whose ages range between
36 and 93 years (median 66). The patients were divided
into two age groups (≤65 and > 65) because an elder (or a
senior citizen) in China is defined as one whose age is
greater than 65. Among the 884 patients, 512 had a KPS
of 90–100 and 372 had a KPS of 80. As to the tumor loca-
tion, 329 patients occurred in the upper section of the
esophagus, 442 occurred in the middle section, and 113
occurred in the lower section. The tumor lengths range
from 3 to 10 cm with the median of 6 cm. In the TNM
classification, T1 was found in 32 patients, T2 in 163, T3
in 305 and T4 in 384; N0 in 461 patients and N1 in 423.
Univariate and multivariate analysis of OS and LC rates
The follow-up times of the patients range from 3 months
to 145 months with the median of 32 months. opre spe-
cifically, 30 patients died in less than 3 months after the
treatment and ten patients lived longer than 145 months
after the treatment. The overall median survival including
death from all causes was 20.3 months. Three and 5-year
OS rates were 37.2 % and 26.6 %, respectively. Five-year
LC rate for the whole group was 47.1 %. To identify the
important prognostic factors, we performed univariate
and multivariate analyses. The univariate analysis data in
Table 1 show how tumor length, T/N stage, AJCC stage,
and treatment modality affected the OS rate and the
LC rate of the patients. The multivariate analysis data
in Table 2 further show that tumor length, AJCC stage,
and treatment modality were independent prognostic
factors for the OS rate and the LC rate of the patients.
Subgroup analyses on OS and LC rates
To further confirm the treatment modality as a prognostic
factor, we compared the two subgroups of patients who
were tested to be early-stage (I + II) or advanced stage
(III). Table 3 shows that the 5-year OS rate and LC rate
for the subgroups of patients who were treated with the
two different modalities. In the stage I + II group, the 5-
year OS rate and LC rate in the patients who were treated
with 3D-CRT were significantly lower than the patients
who were treated with EBRT +NBT (with p = 0.004 and
0.045, respectively, for OS and LC). In the stage III group,
the differences in 5-year OS rate and LC rate between the
two treatment modalities were less obvious (with p = 0.306
and 0.175, respectively, for OS and LC). Figure 2 shows
the differences in OS rate and LC rate between the two
treatment groups.
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Toxicity and pattern of failure
As of the last date of follow-up (March 31, 2013), in the
EBRT +NBT group the total number of failures (includ-
ing local recurrences, remote metastasis, and deaths)
were 326(59.8 %). There were 195 recurrences (35.7 %),
among which 170 (31.2 %) were in-field recurrences and
25 (4.6 %) were out-of-field recurrences. Among the 25
out-of-field recurrences, ten occurred in the supraclavicular
lymph nodes and 15 occurred in the intra-abdominal
lymph nodes. A total of 86 cases (15.8 %) of remote metas-
tasis were found, among which the number of metastasis
to the lung, liver, bone, brain and others (including more
than one organ metastasis) were 23, 14, 14, 5 and 30, re-
spectively. A total of 36 deaths (6.6 %) were found to be
the results of fistula and hematemesis. A total of 45 deaths
(8.2 %) were found to be caused by reasons other than the
original cancer and the radiation treatment.
In the 3D-CRT group, the total number of failures (in-
cluding local recurrences, remote metastasis, and deaths)
were 219 (64.6 %). There are 139 recurrences (41.0 %),
among which 124(39.5 %) were in-field recurrences and
15 (4.4 %) were out-of-field recurrences. Among the 15
out-of-field recurrences, 4 occurred in the supraclavicu-
lar lymph nodes and 11 occurred in the intra-abdominal
lymph nodes. A total of 41 cases (12.1 %) of remote me-
tastasis were found, among which the number of metas-
tasis to the lung, liver, bone, brain and others (including
more than one organ metastasis) were 14, 8, 3, 3 and 13,
respectively. A total of 18 deaths (5.3 %) were found to
be the results of fistula and hematemesis. Four patients
died of second cancer. A total of 35 deaths (10.3 %) were
found to be caused by reasons other than the original
cancer and the radiation treatment.
Table 4 shows the treatment toxicity and the sites of
first failure for the two different treatment groups. In
terms of acute toxicity, no perforations were observed
during this treatment period. Neither was fistulas and
active bleeding observed. However, 634 (71.7 %) patients
developed a Grade ≥ 2 hematologic toxicity, among which
the NBT + EBRT group have significantly higher rates
of leukopenia and thrombocytopenia (with p < 0.001 for
both). There were no significant differences in other
types of acute toxicity between the two groups. For late
toxicity, fistula and massive bleeding were observed in
both groups of patients, of which the 3D-CRT group
show higher rates on both effects.
Discussion
While esophageal cancer radiotherapy technology has
progressed from 2-D CRT to 3-D CRT, and to intensity-
modulated radiotherapy (IMRT), the local recurrence
rates remain unchanged at about 50 % [5, 7]. Myles et.
al. reported long term outcomes of 3D-CRT vs. IMRT
with concurrent chemotherapy for the treatment of
esophageal cancer [8]. They showed that the 5 year OS
rate and median survival time for IMRT (42.2 % and
36 months) were significantly higher than that for 3D-
CRT (31.3 % and 24 months) with p = 0.001. However,
there were no differences in the 5 year LC rate and dis-
tant metastasis free survival between the two groups.
Xiao et. al. reported that 3D-CRT can achieve ideal dose
distribution of providing good coverage to the target vol-
umes and at the same sparing the normal tissues when
Table 3 The 5-year local control (LC) rate and overall survival (OS)
rate for the early-stage (I + II) and advanced stage (III) patients of
the two treatment groups (EBRT + NBT and 3D-CRT)
Characteristics EBRT + NBT 3D-CRT P value
Stage I + II n = 237 n = 126
5-year LC 59.9 % 46.1 % 0.045
5-year OS 43.9 % 28.6 % 0.004
Median survival 45.5 months 25.9 months 0.004
Stage III n = 308 n = 213
5-year LC 44.9 % 33.2 % 0.306
5-year OS 23.2 % 12.8 % 0.175
Median survival 15.6 months 15.5 months 0.175
Overall n = 545 n = 339
5-year LC 51.4 % 38.1 % 0.019
5-year OS 32.0 % 18.4 % 0.001
Median survival 21.7 months 19.1 months 0.001
Abbreviations: EBRT + NBT external beam radiotherapy plus neutron
brachytherapy, 3D-CRT three dimensional conformal radiotherapy
Table 2 Multivariate cox regression analysis of overall survival (OS) rate and local control (LC) rate of the patients
Factors OS rate LC rate
HR (95 % CI) P value HR (95 % CI) P value
Tumor length (≤5 cm vs >5 cm) 0.81 (0.68–0.96) 0.014 0.73 (0.58–0.92) 0.007
T stage (T1 + T2 vs T3 + T4) 0.84 (0.63–1.13) 0.257 0.85 (0.58–1.24) 0.398
N stage (N0 vs N1) 0.89 (0.73–1.09) 0.260 0.90 (0.68–1.18) 0.432
AJCC Stage (I + II vs III) 0.62 (0.52–0.74) <0.0001 0.66 (0.52–0.84) 0.001
Treatment modality (3D–CRT vs NBT + EBRT) 1.27 (1.07–1.20) 0.005 1.26 (1.01–1.58) 0.043
Abbreviations: HR hazard ratio, CI confidence interval, EBRT + NBT external beam radiotherapy plus neutron brachytherapy, 3D-CRT three dimensional
conformal radiotherapy
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compared with the conventional and enlarged field
radiotherapy techniques [9]. Other authors reported
that the patients treated with 3D-CRT have better OS
and LC than that of conventional radiotherapy alone in
many types of cancer [10, 11]. In this study, we found that
NBT + EBRT produced better clinical outcomes than
those of 3D-CRT.
We believe that there are at least two factors making
the NBT + EBRT more effective than 3D-CRT in treating
the localized ESCC. The first factor has to do with the
high-LET nature of fission neutrons of NBT. These neu-
trons are known to be much more effective (than the
low-LET x-ray) in killing the hypoxic tumor cells in lo-
cally advanced cancer. The second factor has to do with
the water being an effective neutron attenuator and that
it can be conveniently injected into the source applicator
during treatment to reduce the neutron dose to the nearby
normal tissue. Because there is a significant difference in
the elasticity between normal tissue and tumor tissue, one
can inject water into the source applicator to effectively
push away the nearby normal tissue while still keep the
tumor tissue close to the source [4].
In terms of radiation related toxicity effects, this study
shows that the NBT + EBRT group showed significantly
Fig. 2 Comparison of the overall survival (OS) rate (a), and local control (LC) rate (b) for patients treated with two different modalities
(EBRT + NBT and 3D-CRT)
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higher rates of leukopenia and thrombocytopenia (P < 0.001
and P < 0.001) than that of the 3D-CRT group. But the
3D-CRT group showed a higher rate of esophageal fis-
tulas. The above differences between the two groups
likely have to do with the differences in their radiation
dose distributions of which the 3D-CRT has a more
uniform dose over the entire target/tumor volume and
the NBT gives an increased dose for the inner part of
the tumor volume.
For long-term survivors from primary cancer, second
primary malignancies (SPMs) are among the most serious
late adverse effects after radiotherapy. Samerdokiene et. al.
recently reported a study on SPMs of 662 long-term survi-
vors with invasive cervical cancer [12]. Among these pa-
tients, 375 were treated with NBT and 287 were treated
with high-dose-rate (HDR) 60Co brachytherapy. The study
reported that no significant difference in rates or distribu-
tion of SPMs was found (21/375 vs 14/287; P = 0.68). Our
study did not include SPMs as most of the esophageal
cancer patients had not survived long enough to develop
SPMs.
An obvious limitation of the reported results is that
they were based on the retrospective study in which the
patients were not randomly assigned. As such, many fac-
tors (e.g. patients’ income level and social status, etc.)
may cause bias of the results.
Conclusions
In this cohort of patients with ESCC treated with NBT +
EBRT were associated with better oncologic outcomes
than those of 3D-CRT. NBT + EBRT were associated with
a higher rate of acute irradiation toxicity. 3D-CRT has the
higher rate of late toxicity esophageal fistulas.
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